Vaxcyte
PCVX
202 hedge funds and large institutions have $5.17B invested in Vaxcyte in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 86 increasing their positions, 58 reducing their positions, and 16 closing their positions.
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
48% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 58
28% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $2.17M
18% more funds holding in top 10
Funds holding in top 10: 11 → 13 (+2)
3% more funds holding
Funds holding: 197 → 202 (+5)
1.26% more ownership
Funds ownership: 106.77% → 108.03% (+1.3%)
3% more capital invested
Capital invested by funds: $5B → $5.17B (+$171M)
Top Buyers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$49.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.3M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$19.4M |
| 4 |
BlackRock
New York
|
+$17.6M |
| 5 |
Jennison Associates
New York
|
+$14.8M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$31.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$20.9M |
| 3 |
FAM
Fred Alger Management
New York
|
-$13.7M |
| 4 |
D.E. Shaw & Co
New York
|
-$13.5M |
| 5 |
PA
Perceptive Advisors
New York
|
-$13.4M |
PCVX Hedge Fund Activity: Q3 2023 in Review
202 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q3 2023, worth a combined $5.17B — up 3.4% from $5B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PCVX positions and 16 closed out — a net gain of 8 holders — while 86 added to existing stakes and 58 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $49.5M. The largest seller was Millennium Management, cutting an estimated $31.1M.
- 202 institutional investors held Vaxcyte (PCVX) as of Q3 2023, up from 197 in Q2 2023.
- Funds reported $5.17B of Vaxcyte stock for Q3 2023, up 3.4% quarter-over-quarter.
- 24 funds opened new Vaxcyte positions in Q3 2023 and 16 closed out, a net change of +8 holders.
- The largest Vaxcyte buyer in Q3 2023 was Westfield Capital Management, an estimated $49.5M added.
- The largest Vaxcyte seller in Q3 2023 was Millennium Management, an estimated $31.1M sold.
Based on aggregated 13F filings for Q3 2023.